842 related articles for article (PubMed ID: 9730852)
21. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
22. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
[TBL] [Abstract][Full Text] [Related]
23. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Ehlers MR; Klaff LJ; D'Alessio DA; Brazg R; Kay HD; Harley RE; Mathisen AL; Schneider R
Horm Metab Res; 2003 Oct; 35(10):611-6. PubMed ID: 14605997
[TBL] [Abstract][Full Text] [Related]
24. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
[TBL] [Abstract][Full Text] [Related]
25. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
Nauck MA; Holst JJ; Willms B; Schmiegel W
Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
[TBL] [Abstract][Full Text] [Related]
26. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
[TBL] [Abstract][Full Text] [Related]
27. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
Gutniak MK; Svartberg J; Hellström PM; Holst JJ; Adner N; Ahrén B
J Intern Med; 2001 Jul; 250(1):81-7. PubMed ID: 11454146
[TBL] [Abstract][Full Text] [Related]
28. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Nauck MA; Meier JJ
Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
Larsen J; Hylleberg B; Ng K; Damsbo P
Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
[TBL] [Abstract][Full Text] [Related]
31. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes.
Torekov SS; Kipnes MS; Harley RE; Holst JJ; Ehlers MR
Diabetes Obes Metab; 2011 Jul; 13(7):639-43. PubMed ID: 21362122
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.
Schirra J; Leicht P; Hildebrand P; Beglinger C; Arnold R; Göke B; Katschinski M
J Endocrinol; 1998 Jan; 156(1):177-86. PubMed ID: 9496247
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint A; Raben A; Astrup A; Holst JJ
J Clin Invest; 1998 Feb; 101(3):515-20. PubMed ID: 9449682
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
Gutniak MK; Linde B; Holst JJ; Efendić S
Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.
Schirra J; Kuwert P; Wank U; Leicht P; Arnold R; Göke B; Katschinski M
Proc Assoc Am Physicians; 1997 Jan; 109(1):84-97. PubMed ID: 9010920
[TBL] [Abstract][Full Text] [Related]
38. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes.
Ahrén B; Holst JJ; Efendic S
J Clin Endocrinol Metab; 2000 Mar; 85(3):1043-8. PubMed ID: 10720037
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes.
Asmar M; Højberg PV; Deacon CF; Hare K; Holst JJ; Madsbad S
Regul Pept; 2010 Feb; 160(1-3):175-80. PubMed ID: 20005261
[TBL] [Abstract][Full Text] [Related]
40. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
